

Unaudited Quarterly Results for the 3rd quarter & period ended 31st December, 2005

(Rs. in Mio)

Particulars	Three Months Ended		Nine Months Ended		Year ended
	(Unaudited)		(Unaudited)		(Audited)
	31.12.2005	31.12.2004	31.12.2005	31.12.2004	31.03.2005
Net Sales/Income from Operations	4090.2	3193.3	10091.6	8735.7	11591.7
Other Income	79.5	40.1	191.5	90.4	165.6
Total Income	4169.7	3233.4	10283.1	8826.1	11757.3
Expenditure					
a. (Increase) / Decrease in Stock in Trade	10.9	55.5	(128.2)	(128.1)	(132.4)
b. Consumption of Raw Materials	2409.2	1717.2	6241.0	4851.5	6574.4
c. Staff Cost	220.0	194.4	589.7	525.6	662.3
d. Other Expenditure	868.1	904.9	2361.8	2521.7	3419.1
Total expenditure	3508.2	2872.0	9064.3	7770.7	10523.4
Profit Before Depreciation, Interest & Tax	661.5	361.4	1218.8	1055.4	1233.9
Interest	162.9	104.2	438.6	279.6	399.9
Depreciation	134.6	125.8	377.8	358.0	404.9
Profit before taxation	364.0	131.4	402.4	417.8	429.8
Provision for Taxation					
a) Current Tax	31.2	9.5	36.1	34.7	40.1
b) Deferred Tax	70.2	23.4	45.9	69.6	38.8
c. Fringe Benefit Tax	0.7	--	1.9	--	--
d) Tax adjustments of previous years	0	(7.4)	0.1	--	(0.5)
Net Profit	261.9	105.9	318.4	311.7	350.7
Paid-up Equity Share Capital (Face value Rs. 5/- per share)	2663.5	2538.5	2663.5	2538.5	2538.5
Reserves excluding Revaluation Reserves	--	--	--	--	7632.0
Earnings per share (Rs.) (not annualised)					
- Basic	4.92	2.09	6.10	6.14	6.91
-Diluted	4.49	2.09	5.81	6.14	6.91
Aggregate of non-promoters Shareholding					
a. Number of Shares			23549057	22939656	22939156
b. Percentage of Shareholding			44.21	45.18	45.18

Notes:

1. The above unaudited results which are subjected to limited review by the Auditors of the Company, were reviewed by the Audit Committee and have been taken on record by the Board at its meeting held on 31.01.2006.
2. Exports constitute Rs.2338.0 millions (Rs.1522.9 millions) of the sales for the quarter.
3. The Company's operations fall within a single primary business segment viz 'Pharmaceutical Products'.
4. Investor complaints pending at the beginning of the quarter: Nil, received: 104, resolved: 104 and lying unresolved at the end of the quarter: Nil.
5. Figures for the previous periods have been rearranged/regrouped wherever necessary.

For and on behalf of the Board

Place: Hyderabad
Date : 31.01.2006

Sd/-
K.Nityananda Reddy
Managing Director